Corbus Pharmaceuticals Holdings, Inc. — Net Income by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/a479b617-413e-4aa1-adb9-cb4e9dcd59b2/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-78.5M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-098530 |
| FY 2024 | $-40.2M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-037335 |
| FY 2023 | $-44.6M | 2023-01-01 – 2023-12-31 | evidence 0000950170-25-037335 |
| FY 2022 | $-42.3M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-006469 |
| FY 2021 | $-45.6M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-003145 |
| FY 2020 | $-111.3M | 2020-01-01 – 2020-12-31 | evidence 0001493152-21-006016 |
| FY 2019 | $-71.5M | 2019-01-01 – 2019-12-31 | evidence 0001493152-20-004077 |
| FY 2018 | $-55.7M | 2018-01-01 – 2018-12-31 | evidence 0001493152-19-003143 |
| FY 2017 | $-32.4M | 2017-01-01 – 2017-12-31 | evidence 0001493152-18-003208 |
| FY 2016 | $-20.0M | 2016-01-01 – 2016-12-31 | evidence 0001493152-17-002256 |
| FY 2015 | $-8.9M | 2015-01-01 – 2015-12-31 | evidence 0001564590-16-015403 |
| FY 2014 | $-2.5M | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-040326 |
| FY 2013 | $-602.4k | 2013-01-01 – 2013-12-31 | evidence 0001193125-15-040326 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Corbus Pharmaceuticals Holdings, Inc. — all facts · Revenue · Operating Income